SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is trending as the community actively coordinates to push the token's visibility on social platforms and trading sites, fueled by an active developer and hopes of reaching higher market caps. While enthusiasts celebrate its organic growth and community-driven approach, skeptics remain vocal about concerns regarding potential volatility, lack of a chart, and typical risks associated with low-cap crypto projects.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally around anticipation of a major upcoming partnership announcement, widely speculated to involve Ripple or XRP, alongside excitement over its new global stablecoin payroll integration with Stellar. While some investors focus on long-term utility and potential listings on major exchanges, community discourse remains polarized between optimistic holders eyeing generational wealth and skeptics dismissing recent price action as a pump-and-dump cycle.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing significant trader attention as a high-performance Layer 1 blockchain, with the community actively debating its potential to rival existing networks through speed and parallel processing. While price action has seen volatility alongside broader crypto market trends, discussions are heavily focused on long-term accumulation, staking rewards, and anticipation of upcoming ecosystem developments.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project's longevity and humorous branding, actively promoting the token's presence across major platforms and cross-promoting with other popular assets. Enthusiasts are focused on organic growth and widespread adoption, frequently engaging with the community through social memes and dedicated poker events.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense social media discussion as the community debates its valuation and high price-to-earnings ratio ahead of its earnings release. While some investors remain cautious about margin pressures and the macro environment, others are highlighting strong unit-level economics, rapid store expansion, and high customer loyalty as reasons to hold the stock through the uncertainty.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently facing significant downward pressure and investor frustration, with the community actively debating whether the stock is a long-term 'holy grail' opportunity or a failing venture as it sits at a critical technical support level. Investors remain highly focused on upcoming manufacturing milestones and the potential for a short squeeze, while sentiment is polarized between those accumulating shares for a multi-year horizon and others disillusioned by the lack of immediate commercial catalysts.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently experiencing significant market movement and high volume driven by intense community speculation regarding a potential buyout or M&A activity. The stock has seen unusual after-hours trading and sustained call option accumulation, leading investors to closely monitor for official announcements or catalyst-driven price volatility.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana (SOL) is trending as the community debates its long-term viability amid heightened scrutiny following the Drift Protocol exploit, while simultaneously balancing bullish sentiment around its expanding DeFi ecosystem and RWA integration. Investors remain divided between concerns over network reliability and regulatory pressure versus optimism for its developer momentum and potential for institutional adoption.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares of Sprout social and Bumble have fallen 76% and 60% respectively, over the past year.&nbsp;</li><li>Snap is expected to report its Q4 earnings on Wednesday and analysts expect it to post a fourth quarter revenue of $1.70 billion, a 9% jump from the same quarter a year-ago, according to data from fiscal.ai.</li><li>Snap saw a 778% rise in its weekly message volume by users on Stocktwits.</li></ul>Shares of Snap have been one of the worst performing among the major social media firms over the past twelve months as uneven advertisement revenue and decline in its users weigh on its stock performance.&nbsp;&nbsp;At the time of writing, shares of Snap have fallen nearly 45% over the past 12 months, only better than DJT, Sprout Social and Bumble, according to data from Koyfin.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Social_media_share_price_comparison_PNG_eba054d644.webp" alt="At the time of writing, shares of Snap have fallen nearly 45% over the past 12 months, only better than DJT, Sprout Social and Bumble, according to data from Koyfin. " width="1037" height="489"></figure>&nbsp;<figure class="table"><table class="ck-table-resized"><colgroup><col><col></colgroup><tbody><tr><td>Company Name</td><td>Stock Price % Change Over Past 12 Months (As of 12:47 AM ET, Feb. 3) Data from Koyfin</td></tr><tr><td>Meta Platforms</td><td>- 0.25%</td></tr><tr><td>Hello Group</td><td>- 8.4%</td></tr><tr><td>Match Group&nbsp;</td><td>-14.98%</td></tr><tr><td>Reddit</td><td>- 18.08%</td></tr><tr><td>Pinterest</td><td>- 37.63%&nbsp;</td></tr><tr><td>Weibo Corporation</td><td>2.05%&nbsp;</td></tr><tr><td>NetEase</td><td>14.39%</td></tr><tr><td>Yalla Group</td><td>73.17%</td></tr></tbody></table></figure>&nbsp;At the time of writing, Snap stock was down nearly 6% and was among the trending stocks on the Stocktwits platform. Snap saw a 778% rise in its weekly message volume by users on Stocktwits.<h2 class="st-heading-2">Snap’s Q4 Earnings Due</h2>Snap is expected to post a fourth quarter (Q4) revenue of $1.70 billion, a 9% jump from the same quarter a year-ago, according to data from fiscal.ai.Wall Street expects the company to post a profit of $0.15 per share, almost flat from the same year-ago quarter. The company had missed profit estimates for the third and second quarter of 2025.&nbsp;Earlier, Roth Capital said it remains cautious on Snap shares heading into earnings as it sees sequential decline in users to weigh on any revenue or Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) upside. It raised the firm's price target on Snap to $10 from $9 and kept a ‘Neutral’ rating on the shares.UBS said that the Q4 earnings outlook for advertising-driven companies’ points to slimmer beats after a slow October tied to a government shutdown, followed by a rebound in November and December.<h2 class="st-heading-2">Retail Chatter On Stocktwits</h2>Retail sentiment around SNAP trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One Stocktwits user said that they are long on Meta Platforms and short on Snap.&nbsp;<stembedurl>https://stocktwits.com/John___wick44/message/643817145</stembedurl>Another bearish user predicted the Snap stock to hit $4 on Wednesday.&nbsp;<stembedurl>https://stocktwits.com/Jamolo/message/643814826</stembedurl>Another user said that they sold SNAP stock with a $2000 loss.&nbsp;<stembedurl>https://stocktwits.com/slmaster/message/643811254</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Snap Inc. is displayed on a smartphone screen.

This Stock Is Among The Laggards In Social Media Companies — Here’s What Wall Street Expects From Its Q4 Earnings Tomorrow

Snap shares have fallen nearly 45% over the past 12 months, only better than DJT, Sprout Social and Bumble over the same period.

Equity

<ul class="summary-bullets"><li>Roth Capital said it remains cautious on Snap shares heading into earnings as it sees sequential decline in users to weigh on any revenue or EBITDA upside.</li><li>UBS lowered the firm's price target on Snap to $9 from $10.</li><li>On Tuesday, in order to meet the requirements of Australia's Social Media Minimum Age, the company disabled over 415,000 Snapchat accounts in Australia.&nbsp;</li></ul>Shares of social media platform Snap fell nearly 3% on Monday as investors turned their focus to Wednesday’s earnings announcement.&nbsp;At the time of writing, Snap stock was down nearly 4% and was among the trending stocks on the Stocktwits platform.&nbsp;<h2 class="st-heading-2">Q4 Earnings Preview</h2>Snap is expected to post a fourth quarter (Q4) revenue of $1.70 billion, a 9% jump from the same quarter a year-ago, according to data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">fiscal.ai</a>.Wall Street expects the company to post a profit of $0.15 per share, almost flat from the same year-ago quarter. The company had missed profit estimates for the third and second quarter of 2025.&nbsp;Earlier, Roth Capital said it remains cautious on Snap shares heading into earnings as it sees sequential decline in users to weigh on any revenue or EBITDA upside. Perplexity deal launch and AR glasses announcement are among the catalysts to get constructive on the stock in the first half of the year, the firm added. It raised the firm's price target on Snap to $10 from $9 and kept a ‘Neutral’ rating on the shares.UBS, however, lowered the firm's price target on Snap to $9 from $10 and kept a ‘Neutral’ rating on the shares.&nbsp;UBS said that the Q4 earnings outlook for advertising-driven companies’ points to slimmer beats after a slow October tied to a government shutdown, followed by a rebound in November and December.&nbsp;<h2 class="st-heading-2">Recent News</h2>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/01/20/technology/snap-social-media-addiction-lawsuit.html">report</a> from the New York Times, Snap agreed to settle a tech addiction lawsuit ahead of a landmark trial alleging social media companies engineered addictive products that harm young users.&nbsp;On Tuesday, it announced that in order to meet the requirements of the Australia's Social Media Minimum Age (SMMA), the company, as of the end of January 2026, has locked or disabled over 415,000 Snapchat accounts in Australia belonging to users who either declared an age under 16 or were believed to be under 16 based on its age detection technology.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users’ React?</h2>Retail sentiment around SNAP trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user said the stock has low downside risk and the upside is attractive.&nbsp;<stembedurl>https://stocktwits.com/PStevenson/message/643724512</stembedurl>Shares in the company have fallen 39.5% over the past 12 months.&nbsp;

In this photo illustration, a person holds a smartphone displaying the logo of Snap Inc. (NYSE: SNAP), the parent company of Snapchat, on July 31, 2025, in Chongqing, China. 

Snap Shares Are Tumbling Today As Focus Turns To Q4 Earnings – What Are Investors Expecting?

 The Wall Street expects the company to post a profit of $0.15 per share, almost flat from the same year-ago quarter.

<ul class="summary-bullets"><li>It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the analyst expectations of $7.21 per share.</li><li>The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt.</li><li>Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.</li></ul>Shares of Whirlpool slumped more than 8% on Thursday as weak fourth-quarter earnings and lower forecast for FY26 disappointed investors.&nbsp;The weak forecast prompted strong criticism from the retail traders on the performance of the company.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WHR trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bearish user on Whirlpool's earnings said, “Disappointment again? That’s only like 20 quarters in a row”.&nbsp;<stembedurl>https://stocktwits.com/Siksika/message/643306159</stembedurl>Another user on Stocktwits predicted that “the dividend is going to get cut or eliminated. They don’t have the cash this year from operations to fund their dividend.”<stembedurl>https://stocktwits.com/freddycan/message/643262444</stembedurl><h2 class="st-heading-2">Weak Forecast</h2>The company said on a full year basis in 2026, it expects net sales of $15.3 - $15.6 billion; approximately 5% growth vs 2025 like-for-like.&nbsp;It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the expectations of $7.21 per share by analysts.&nbsp;The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt that align with its capital allocation priorities and maximize shareholder value.&nbsp;“Price/mix to favorably impact our EBIT margin as we continue to deliver new product innovation and realize the momentum of our 2025 launches,” it said in a statement.&nbsp;<h2 class="st-heading-2">Earnings Miss</h2>The company reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.Its revenue of $4.1 billion also came below analysts’ expectations of $4.27 billion. Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.&nbsp;“With a challenging 2025 behind us, our confidence for 2026 is based on our recent successful product launches, reduced promotional intensity and a gradual recovery of the housing market,” said CEO Marc Bitzer.&nbsp; &nbsp;

Close-up of logo for appliance company Whirlpool on a clothes dryer in a domestic room, August 21, 2019. 

WHR Slips 7% — Why Is Retail Expecting Whirlpool To Eliminate Dividend?

Whirlpool reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.

<ul class="summary-bullets"><li>Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.”</li><li>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment.</li><li>Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025.</li></ul> Shares of Sarepta Therapeutics Inc. (SRPT) sank 12% on Monday after the company said that it expects full year 2025 net product revenue of $1.86 billion, marking only slight growth from the $1.79 billion reported for full year 2024.Net product revenue refers to the company’s revenue from its products and does not include collaboration, contract manufacturing or royalty revenue.Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025, according to data from Fiscal AI.<h2 class="st-heading-2">Results Breakdown</h2>Sarepta <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025">now sees</a> revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million, including fourth quarter revenue of $110.4 million. The company said that the therapy’s revenue in the three months through the end of December was impacted by the year-end flu season and the need to reschedule six patient infusions into 2026.Revenue from the company’s other therapies for the full year is now expected at $965.6 million.Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” “We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS. We previously set a yearly sales floor for ELEVIDYS of $500.0 million. We reconfirm that floor and our intentions to exceed it,” Ingram said on Monday.The company further added that it had $953.8 million in preliminary cash, cash equivalents, restricted cash and investments as of 2025-end. The company will announce its full financial results in late February.<h2 class="st-heading-2">Elevidys Safety Concerns And Other Setbacks</h2>The preliminary numbers come in light of a challenging year for the company. Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in the particular patient segment.In November, the company also announced that its two approved therapies Amondys 45 and Vyondys 53 in DMD failed in a key confirmatory trial aimed at a traditional full approval for the two. The company, however, continues to eye traditional approval based on the positive risk-benefits of the therapies and real-world evidence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from 'high’ to 'extremely high' levels.A Stocktwits user dismissed the sell-off and opined that the “Elevidys story isn’t broken.” They also noted that the company has enough cash to cover liabilities.<stembedurl>https://www.stocktwits.com/Initiator1/message/641562456</stembedurl>Another dismissed the selloff as a "minor setback."<stembedurl>https://www.stocktwits.com/ZzyzxResearch/message/641561010</stembedurl><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 82% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-lvlu-stock-surge-today/cmUaI8XR4Eo">Why Did LVLU Stock More Than Double Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.

<ul class="summary-bullets"><li>Coty is entitled to receive 45% of any proceeds from a future sale and IPO of Wella.</li><li>Coty said the sale completes a programme launched in 2020 to streamline its operations and realise the full value of Wella.&nbsp;</li><li>Coty said it will use the majority of Wella’s upfront cash proceeds to pay down its short-term and long-term debt.</li></ul>Beauty company Coty (<a href="https://stocktwits.com/symbol/COTY">COTY</a>) has sold its remaining 25.8% stake in Wella to private equity firm KKR for an upfront cash payment of $775 million, while retaining the right to receive 45% of proceeds from Wella’s future sale or IPO.&nbsp;Coty said the sale of Wella completes the program initiated in 2020 to simplify Coty’s portfolio and operations, while realising the full value of its Wella business.“This transaction marks a pivotal milestone for Coty – both in our transformation and in our long-running deleveraging commitment," said Laurent Mercier, Coty CFO.&nbsp;<h2 class="st-heading-2">Declining Sales, Rising Debt</h2>Coty has been facing pressure from declining sales and profits as higher inflation and uncertainty about the health of the U.S. economy have prompted consumers to cut back on discretionary spending on fragrance and beauty products.Coty said it will use the majority of Wella’s upfront cash proceeds to pay down its short-term and long-term debt. In the first quarter ended Sept. 30, 2025, of its fiscal year 2026, Coty’s total debt increased by nearly 2% to $4.07 billion compared to the same period last year.Coty anticipates that proceeds from the Wella transaction, together with expected free cash flow of over $350 million in the first half of FY26, will reduce its financial net leverage to about 3x by the end of calendar year 2025.Its adjusted profit of $0.12 per share in the first quarter (Q1) of fiscal year 2026 was below analyst expectations of $0.15 per share, according to Fiscal.ai. The company delivered net sales of $1.58 billion, down 6% from the year-ago period but in line with analyst projections.Earlier, it had also launched a strategic review of other beauty brands, such as Rimmel and CoverGirl, to streamline its operations and shift its focus to the fragrance segment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for COTY trended in “neutral” territory amid “extremely low” message volume.<figure class="image"><img style="aspect-ratio:638/69;" src="https://news.stocktwits-cdn.com/coty_PNG_6c7394d388.webp" alt="Retail sentiment on Stocktwits for COTY trended in “neutral” territory amid “extremely low” message volume." width="638" height="69"></figure>Shares in Coty have fallen more than 50% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the Coty Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did Coty Offload Wella From Its Portfolio?

Coty has sold its remaining 25.8% stake in Wella to KKR-managed capital accounts and investment affiliates for an upfront cash payment of $775 million. 

<ul class="summary-bullets"><li>Sarepta is set to exchange 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030, alongside about $31.6 million in cash.</li><li>The transaction is slated to be completed around Dec. 18, 2025.&nbsp;</li><li>The deal would involve the purchase of approximately 691,000 SRPT common stock, the company said.&nbsp;</li></ul>Sarepta Therapeutics Inc. (SRPT) shares tumbled more than 6% on Thursday after the company announced a debt refinancing plan totaling about $291 million.&nbsp;The drug manufacturer said that, as per the privately negotiated agreements, it would exchange $291.4 million of 1.25% convertible senior notes due 2027 for the same amount of new 4.875% convertible senior notes due 2030 alongside about $31.6 million in cash.The deal is expected to close around Dec. 18, 2025.&nbsp;<h2 class="st-heading-2">Deal Details</h2>After the debt refinancing, the aggregate principal amount of SRPT’s 4.875% convertible senior notes due 2030 will be approximately $893.4 million. This would result in $158.6 million in aggregate principal amount of the existing notes to remain outstanding under the previous terms, the company said.&nbsp;The transaction would also entail the sale by the private parties of approximately 691,000 shares of the company’s common stock,&nbsp;which could affect the market price of the company’s shares and notes, the firm noted. Since the deal is private, none of the new notes and shares issuable upon conversion are registered for public sale.Most recently,&nbsp;<a href="https://stocktwits.com/symbol/SRPT/">SRPT</a> issued an equity grant of about $12 million to Douglas S. Ingram, its chief executive officer. In November, the company also received FDA approval to begin a new study to test the impact of immunosuppressant sirolimus on liver injury in non-ambulatory Duchenne patients.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, SRPT was among the top 10 trending stocks on Thursday morning. The retail sentiment around SRPT jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1290/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_8_56_01_PM_png_5f8dc3f44e.webp" alt="SRPT stock sentiment and message volume." width="1290" height="150"></figure>Shares of SRPT are down over 83% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Is SRPT Stock Falling Today?

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 

<ul class="summary-bullets"><li>The fresh study cohort will enroll about 25 DMD patients in the U.S. who cannot walk.</li><li>The company intends to initiate the study cohort by the end of this year.</li><li>Elevidys, a medicine intended for the treatment of DMD, created safety concerns following the death of two patients after treatment earlier this year.</li></ul> Sarepta Therapeutics, Inc. (SRPT) on Tuesday said that the U.S. Food and Drug Administration (FDA) has approved dosing in a study cohort to evaluate the use of an immunosuppressive regimen as part of treatment with Elevidys gene therapy for Duchenne muscular dystrophy patients.<a href="https://stocktwits.com/symbol/SRPT">SRPT shares</a> gained nearly 1% on Tuesday morning at the time of writing.<h2 class="st-heading-2">Study Plans</h2>The data from the study cohort will be used to determine whether administering Sirolimus before and after the Elevidys infusion can help reduce acute liver injury in patients who cannot walk, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-approval-begin-endeavor-cohort-8-evaluate">said</a>. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.The study cohort will enroll about 25 patients in the U.S. who are unable to walk. They will be treated with 14 days of peri-infusion Sirolimus dosing before Elevidys administration and 12 weeks after administration. &nbsp;“We plan to initiate Cohort 8 by the end of this year and pending enrollment, complete primary endpoint data collection in the second half of 2026,” said Louise Rodino-Klapac, president of research and development and technical operations at Sarepta.<h2 class="st-heading-2">Sarepta’s Rocky Road With Elevidys</h2>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause earlier this year, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in this particular patient segment.However, a Citi analyst said in August that the U.S. Food and Drug Administration may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. The agency may take a “more comprehensive look” at the level of immunomodulation required for Elevidys, the analyst had then said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.SRPT stock is down 84% this year and by 83% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lnai-stock-soars-pre-market-after-immune-cell-therapy-gains-licensee-interest/cL520F1REXu">LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys

Data from a study cohort will be used to determine whether administering Sirolimus before and after the Elevidys infusion can help reduce acute liver injury, the company said. 

<ul class="summary-bullets"><li>Merck is currently evaluating Sac-TMT in 15 global late-stage trials spanning six tumor types, including breast, endometrial, and lung cancers.</li><li>Separately, the company also said that it has now assumed full responsibility for the development of MK-8690, an investigational drug targeting inflammatory bowel diseases.&nbsp; &nbsp;</li></ul>Shares of Merck (MRK) traded 1% higher on Tuesday afternoon after the company said that it has entered into a funding agreement with Blackstone Life Sciences to advance its experimental cancer drug.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-enters-into-research-and-development-funding-agreement-with-blackstone-life-sciences-for-sacituzumab-tirumotecan-sac-tmt/">deal</a>, Blackstone will pay Merck $700 million to fund a portion of the development costs for Sacituzumab Tirumotecan or Sac-TMT, an investigational antibody-drug conjugate. An antibody-drug conjugate (ADC) is a type of cancer therapy that combines a targeted antibody with a chemotherapy drug to deliver the drug directly to cancer cells, minimizing damage to healthy cells.<h2 class="st-heading-2">Terms Of The Funding Deal</h2>Merck is currently evaluating the drug in 15 global late-stage trials spanning six tumor types, including breast, endometrial, and lung cancers. The funding agreement will help fund a portion of the development costs in 2026.Blackstone, in return, will be eligible to receive low-to-mid single-digit royalties on net sales of the drug contingent upon receipt of regulatory approval in the U.S. for first-line treatment of triple-negative breast cancer. Blackstone, however, will not receive any right to the drug.Sac-TMT was developed by Sichuan Kelun Pharmaceutical Co. The company granted Merck the exclusive rights to develop, manufacture, and commercialize sac-TMT in all territories outside of Greater China, including Mainland China, Hong Kong, Macau, and Taiwan, under a deal.<h2 class="st-heading-2">Merck Assumes Responsibility For MK-8690</h2>Separately, Merck <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-signs-agreement-with-dr-falk-pharma-gmbh-for-certain-development-and-commercialization-rights-to-mk-8690-pra-052-an-investigational-anti-cd30-ligand-monoclonal-antibody/">announced</a> on Tuesday that it has reached an agreement through a unit with Germany’s Dr. Falk Pharma GmbH to discontinue a contract signed in 2020 concerning co-development and co-commercialization rights in certain territories for MK-8690, an investigational drug targeting inflammatory bowel diseases. Merck has now assumed full responsibility for the development program.Dr. Falk will receive $150 million upfront as part of the deal termination and will continue to be eligible to receive payments associated with development milestones, as well as royalties on sales in certain territories.Merck said that it will record a pre-tax charge to research and development expenses of $150 million, or approximately $0.05 per share, in its fourth quarter results as a result of the discontinuation of the deal.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">MRK stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="data:image/png;base64,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" width="624" height="63" alt="MRK's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>MRK's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure> MRK stock is down 16% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/evok-stock-doubled-in-value-post-qol-medical-deal/cL28jriR36q">EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug

The deal will fund a portion of the development costs for Sacituzumab Tirumotecan, also known as Sac-TMT. 

<ul class="summary-bullets"><li>In addition to the upfront payment of $8.875 billion, Thermo Fisher has agreed to $125 million in January 2027 and up to $400 million of earn-out payments based on the performance of the business in 2026 and 2027.&nbsp;</li><li>The transaction is expected to be completed by the middle of 2026.</li><li>Thermo Fisher expects the acquisition to be immediately accretive to its adjusted operating margin. &nbsp;</li></ul>Thermo Fisher Scientific Inc. (TMO) said on Wednesday that it has entered into a definitive agreement to acquire data solutions provider Clario Holdings for $8.875 billion in cash at close in a bid to accelerate its data capabilities and advance clinical research.In addition to the upfront payment, Thermo Fisher has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2025/Thermo-Fisher-Scientific-to-Acquire-Clario-Holdings-Inc--Enabling-Pharma-and-Biotech-Customers-to-Accelerate-Innovation-with-Deeper-Clinical-Insights/default.aspx">agreed</a> to $125 million in January 2027 and up to $400 million in earn-out payments based on the performance of the business in 2026 and 2027, bringing the total deal value to $9.4 billion.<h2 class="st-heading-2">Transaction Impact</h2>The transaction is expected to be completed by the middle of 2026, subject to customary closing conditions and approvals from regulators. Upon closing of the deal, Clario will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.Thermo Fisher expects the acquisition to be immediately accretive to its adjusted operating margin. It also expects the deal to add $0.45 of adjusted earnings per share in the first year after closing.For the full year 2025, Clario is expected to generate approximately $1.25 billion of revenue. Thermo Fisher added that Clario's business is expected to grow in the high single-digits under its ownership.Clario’s clinical trial endpoint data can support faster, more confident trial decisions, Thermo Fisher noted. Clinical trial endpoint data refers to the specific outcomes or events that are measured to determine whether the treatment being studied is effective and safe, and is essential for regulatory approvals in addition to pipeline development.Earlier this week, the Financial Times had reported that Thermo Fisher is nearing a takeover of Clario.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TMO">TMO stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘low’ levels.The latest acquisition marks Thermo Fisher’s third major acquisition this year, including the acquisition of Sanofi’s Ridgefield, New Jersey site to expand U.S. drug product manufacturing and the buyout of the purification and filtration business of Solventum (SOLV) for about $4 billion in cash.TMO stock is up by 7% this year and by about 2% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/adidas-apparel-surge-fuels-record-revenue-amid-tariff-turbulence/cLGZjg8R3wG">Adidas’ Apparel Surge Fuels Record Revenue Amid Tariff Turbulence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Thermo Fisher Scientific raised its full-year adjusted EPS guidance to a new range of $21.35 to $22.07 | Image Source: Thermo Fisher

Thermo Fisher Adds Clario Holdings In A $9.4B Deal – Its Third Acquisition In 2025

Thermo Fisher expects the acquisition to be immediately accretive to its adjusted operating margin.

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

Advisorshares Trust - AdvisorShares Dorsey Wright Short ETF -1x Shares

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

DWSH
AdvisorShares Dorsey Wright Short ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DWSH News

DWSHAdvisorShares Dorsey Wright Short ETF